ANAnisa Dias Nur'AIni

Anisa Dias Nur'AIni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anisa Dias Nur'AIni has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    La curcumina y sus derivados como posibles candidatos antivirales contra la viruela del mono (mpox): una revisión de estudios computacionales

    by Fiki Muhammad Ridho, Anisa Dias Nur'AIni, Hamnah Al Atsariyah, Andika Julyanto Syachputra, Wisnu Eka Wardana, Andang Nurhuda

    Introduction: Monkeypox (mpox) is an infectious disease caused by the mpox virus that is of global health concern because the outbreak, as of May 2023, has affected more than 80,000 people in hundreds of countries. Currently, there is no specific treatment, including antivirals, for mpox patients. Exploration of active compounds for mpox continues, one of which is curcumin and its derivatives. Curcumin is a polyphenol compound predominantly found in turmeric which has been documented to have antiviral effects. Therefore, this study aims to explore studies investigating the potential of curcumin and its derivatives as antiviral candidates in targeting mpox. Method: Literature published from inception to 2024 in ScienceDirect, PubMed, Scopus, and Google Scholar was searched. Keywords used in this search included curcuma, curcumin, tetrahydrocurcumin, demethoxycurcumin, bisdemethoxycurcumin, turmeric, monkeypox, and mpox. Results: The literature search results found five computational studies involving the compound curcumin and its derivatives, including tetrahydroxycurcumin and demethoxycurcumin. All studies showed that curcumin and its derivatives have better binding affinity with mpox proteins compared to control of several antivirals. Curcumin and its derivatives have strong potential in inhibiting mpox virus replication and modulating the immune system. Conclusions: This review concludes that curcumin and its derivatives have potential as antiviral candidates for mpox. However, related studies remain limited and confined to computational studies. Further preclinical experimental and clinical studies are needed to confirm their effectiveness and mechanisms of action.


  • Open Access

    PRE-CLINICAL AND CLINICAL EFFICACY OF CURCUMIN AS AN ANTI-INFLAMMATORY AGENT FOR PERIODONTITIS. A SYSTEMATIC REVIEW

    by Fiki Muhammad Ridho, Andika Julyanto Syachputra, Anisa Dias Nur’aIni, Kamailiya Ulfah, Muhamad Faqih, Andang Nurhuda

    Introduction: There is ongoing exploration into herbal treatments to identify adjunct therapies with minimal side effects. One such treatment involves curcumin from turmeric (Curcuma longa). This study aims to review the efficacy of curcumin as an anti-inflammatory agent for periodontitis along with the mechanisms of action involved. Methods: A systematic review of pre-clinical and clinical studies published on Scopus, PubMed, ScienceDirect, and Google Scholar up to May 2024 was employed following the PRISMA guidelines. Three tools were used for risk of bias assessment, namely the QUIN tool for in vitro studies, the SYRCLE’s RoB for in vivo studies, and the Cochrane RoB 2 for RCTs. Finally, nineteen studies were included for review. Results: This study highlights curcumin’s efficacy in addressing periodontitis through diverse mechanisms. Curcumin demonstrated efficacy in attenuating inflammation within periodontal tissue by inhibiting several pro-inflammatory cytokines and mediators such as interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-α, matrix metalloproteinases (MMPs), prostaglandin E2 (PGE2), cyclooxygenase (COX)-2, while concurrently increasing IL-4 and IL-10. In addition, several transcription factors such as nuclear factor-kappa B (NF-κB) and signal transducer and activator of transcription 1 (STAT1) were also inhibited by curcumin. Administration of curcumin has additionally been demonstrated to reduce other biomarkers of periodontitis, including C-reactive protein (CRP), alkaline phosphatase (ALP), and procalcitonin (PCT). Conclusion: Curcumin has been shown to be effective as an adjunct therapeutic agent for periodontitis due to its anti-inflammatory effects by reducing the inflammatory response through a diverse range of mechanisms of action.